Onartuzumab (MetMab): Using nonclinical pharmacokinetic and concentration-effect data to support clinical development

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5068-5078

  Xiang, Hong ^a,b   Bender, Brendan C ^a   Reyes II, Arthur E ^a   Merchant, Mark ^a   Shasha Jumbe, Nelson L ^c   Romero, Mally ^e   Davancaze, Teresa ^a   Nijem, Ihsan ^a   Mai, Elaine ^a   Young, Judy ^a   Peterson, Amy ^d   Damico Beyer, Lisa A ^b  

^a Department of Pharmacokinetic and Pharmacodynamic Sciences ^*  (United States)

^b GENENTECH INC   (United States)

^c Quantitative Solutions   (United States)

^d Medivation Inc   (United States)

^e CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONARTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MACACA FASCICULARIS; MICE; MICE, NUDE; MONTE CARLO METHOD; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884574183     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0260     Document Type: Article

References (38)

1. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000;40:67-95.
2. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 2005;7:E544-59.
3. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 2007;43:1862-8.
4. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26:1596-602.
5. Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, et al. Bridging the gap between preclinical and clinical studies using pharmacokineticpharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res 2012;18:3090-9.
6. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 2010;37:221-42.
7. Jadhav PR. Leveraging prior knowledge in guiding drug development and regulatory decisions. 8th Kitasato University-Harvard School of Public Health Symposium; Tokyo, Japan; 2008.
8. Birchmeier C, Birchmeier W, Gherardi E, Van de Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
9. Gherardi E, Birchmeier W, Birchmeier C, Vande Woods G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
10. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 1991;49:323-8.
11. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met Tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993;123:223-35.
12. Eder JP, Van de Woude GF, Boerner SA, Lo Russo PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14.
13. Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther 2012;12:519-28.
14. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factorneutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16:699-710.
15. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncol 2011;13:437-46.
16. Jones SF, Cohen RB, Bendell JC. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. J Clin Oncol 28:15s, 2010 (suppl; abstr 3081).
17. Patnaik A, Weiss GJ, Papadopoulos K, Tibes R, Tolcher AW, Payumo FC, et al. Phase I study of SCH900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2525).
18. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
19. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. Met MAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-8.
20. Merchant M, Ma X, Maun HR, Zhang Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013;110:E2987-96.
21. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004;6:75-84.
22. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996;9:617-21.
23. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998;111:237-47.
24. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, et al. Durable complete response of metastiatic gastric cancer with anti-MET therapy followed by resistance at recurrence. Cancer Discov 2011;1:573-9.
25. Moss RA, Patel P, Bothos J, Peterson AC, Eppler S, Yu W, et al. Complete results from phase Ia/Ib dose-escalation study of Met MAb, a monovalent antagonist antibody to the receptor Met, dosed as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Ann Oncol 2010;21(Suppl. 8):504P.
26. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating Met MAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29:2011 (suppl; abstr 7505).
27. Beal, SL, Sheiner, LB, Boeckmann, A, Bauer, RJ. NONMEM User's Guides (1989-2009), Icon Development Solutions, Ellicott City, MD, USA, 2009.
28. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 2011;3:61-6.
29. Han C, Zhou H. Monoclonal antibodies: interspecies scaling with minimal preclinical information. Ther Deliv 2011;2:359-68.
30. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:633-59.
31. Xiang H, Reyes A, Merchant M, Bender B., Jumbe N., Young J., et al. Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information. Eur J Cancer Suppl 2008;6:167.
32. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006;72:1-10.
33. Pisters LL, el-Naggar AK, Luo W, Malpica A, Lin SH. C-met protooncogene expression in benign and malignant human renal tissues. J Urol 1997;158:724-8.
34. Lindemann K, Resau J, Nahrig J, Kort E, Leeser B, Annecke K, et al. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 2007;51:54-62.
35. Trejtnar F, Laznicek M. Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med 2002;46:181-94.
36. Bai S, Xin Y, Jin D, Kaur S, Nijem I, Bothos JG, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, MetMAb, in patients with advanced solid tumors. J Clin Oncol 29, 2011 (suppl; abstract 2571).
37. Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol 2013; DOI: 10.1002/jcph.148.
38. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999;27:14-21.